Compare IPI & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | RXST |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.0M | 305.0M |
| IPO Year | 2007 | 2021 |
| Metric | IPI | RXST |
|---|---|---|
| Price | $37.79 | $7.12 |
| Analyst Decision | Strong Sell | Hold |
| Analyst Count | 1 | 10 |
| Target Price | ★ $25.00 | $9.78 |
| AVG Volume (30 Days) | 425.4K | ★ 685.7K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.14 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $298,328,000.00 | $134,479,000.00 |
| Revenue This Year | $5.01 | N/A |
| Revenue Next Year | N/A | $9.91 |
| P/E Ratio | $43.94 | ★ N/A |
| Revenue Growth | ★ 17.13 | N/A |
| 52 Week Low | $22.55 | $5.90 |
| 52 Week High | $50.34 | $16.73 |
| Indicator | IPI | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 50.77 |
| Support Level | $37.00 | $6.62 |
| Resistance Level | $49.06 | $9.11 |
| Average True Range (ATR) | 3.31 | 0.39 |
| MACD | -0.93 | 0.13 |
| Stochastic Oscillator | 7.32 | 85.97 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, which is also the location of the firm's production facilities.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.